vancomycin has been researched along with pc190723 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baker, N; Bennett, JM; Chauhan, PK; Collins, I; Czaplewski, LG; Davies, DT; Gavade, M; Haydon, DJ; Kumar, D; Lancett, P; Macdonald, R; Macleod, L; Mahajan, A; Mitchell, JP; Nayal, N; Nayal, YN; Pitt, GR; Singh, M; Srivastava, A; Stokes, NR; Yadav, A | 1 |
Bi, F; Liu, X; Ma, S; Qin, Y; Song, D; Teng, Y; Zhang, N; Zhang, P | 1 |
Kaul, M; LaVoie, EJ; Lyu, YL; Mark, L; Parhi, AK; Pawlak, J; Pilch, DS; Saravolatz, LD; Saravolatz, S; Weinstein, MP; Zhang, Y | 1 |
3 other study(ies) available for vancomycin and pc190723
Article | Year |
---|---|
Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Benzamides; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Oxazoles; Staphylococcus aureus; Structure-Activity Relationship | 2014 |
Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
Topics: Bacterial Proteins; Benzamides; Cytoskeletal Proteins; Methicillin-Resistant Staphylococcus aureus | 2019 |
TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Benzamides; Cells, Cultured; Cytoskeletal Proteins; Daptomycin; Dogs; Half-Life; Humans; Linezolid; Methicillin; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Prodrugs; Pyridines; Rats; Staphylococcal Infections; Thiazoles; Vancomycin | 2015 |